Craig W A
Department of Medicine, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705, USA.
Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. doi: 10.1086/516284.
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
过去20年的研究表明，抗菌药物在抗菌活性的时间过程中可能有显著差异。这些药效学活性的差异对最佳给药方案有影响。最近的研究结果表明，在动物感染模型和人类感染中，产生疗效所需的药代动力学/药效学参数的大小相对相似。然而，仍有许多需要了解的地方。需要进行更多研究，以进一步将许多抗菌药物的药代动力学/药效学参数与各种动物感染模型和人类感染中的治疗效果相关联。将药代动力学/药效学参数用作指导原则，为新药和旧药、新出现的病原体和耐药菌建立最佳给药方案，设定药敏折点以及降低药物开发成本，其潜在价值应使继续探索小鼠和人类抗菌给药的治疗原理变得有价值。
